Manzo Pharmaceuticals(OTC) MNZO

Manzo Pharmaceuticals, Inc. is a specialized drug company focused on the discovery and development of proprietary and generic medical treatments. The company is actively working on Lacto-Freedom, a patented probiotic aimed at aiding individuals with lactose intolerance, and is also developing a natural solution for infant colic.

Products and Services

• Lacto-Freedom: A patented probiotic for lactose intolerance
• Natural solution for infant colic
• Research and development of additional therapies

Growth Outlook

• Recent quarterly revenue of $60,000 indicates potential for growth
• Focus on innovative treatments may attract new market segments
• Development of proprietary products could enhance competitive advantage

Financial Highlights

• Trailing twelve months (TTM) revenue shows a significant increase
• Recent net income of $7,261 reflects operational improvements
• Cash flow coverage ratio of 4.58 suggests strong liquidity management

Manzo Pharmaceuticals, Inc. operates in the healthcare sector, specifically within the drug manufacturing industry. The company is headquartered in Milford, Pennsylvania, and has a small team of 12 employees. The focus on innovative solutions for common health issues positions Manzo Pharmaceuticals as a potential player in the growing market for specialty and generic drugs. The recent financial performance, including a notable quarterly revenue and positive cash flow metrics, indicates a promising trajectory for future growth. Investors may find the company's commitment to developing effective treatments appealing, especially in light of the increasing demand for health solutions.